Status: Recruiting
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.
Participants needed: 51
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Guangdong Hengrui Pharmaceutical Co., LtdUpdated: Dec 1, 2025Locations: 1
Eligibility criteria
Age 18-70 years (inclusive) at informed consent signing, regardless of sex; [+4]
Received renal dialysis within 12 months preceding screening, or anticipated req... [+5]